13F Filings/Crestline Management, L.P.

Crestline Management, L.P.

Hedge FundCIK0001536054LocationFORT WORTH, TX 76102, United States

Long U.S. equity positions disclosed to the SEC on Form 13F-HR.

Latest filingQ2 2026Quarter ended30 Jun 2026Filed14 Aug 2026
Firm profile · Form ADV
SEC adviser registration

Founded in 1997 and indirectly owned by Rithm Capital Corp., Crestline Management, L.P. is an institutional alternative investment manager that provides discretionary management services to private pooled investment funds and private managed accounts. The firm specializes in credit and opportunistic investments—including lending, financing and restructuring solutions for mature private equity funds, and beta and hedging solutions forSummarised from the firm’s Form ADV Part 2A brochure.

CRD
122711 · 801-61607
Portfolio Turnover
7%
Of book traded, QoQ
Positions
3
Long U.S. equities
Top 10 Concentration
100%
Of reported value
QoQ Change
$7.2M
Value change
Assets under management
Form ADV RAUM · client mix · 13F over time
Regulatory AUM
$22.5B
Form ADV, as of Mar 2026
● 100% discretionary ($22.5B)
By client type
Pooled investment vehicles: $12.6B (55.9%) · 100 clients
Pooled investment vehicles
$12.6B · 56%
Pension & profit-sharing plans: $4.8B (21.5%) · 9 clients
Pension & profit-sharing plans
$4.8B · 22%
Insurance companies: $2.6B (11.6%) · 5 clients
Insurance companies
$2.6B · 12%
Sovereign wealth funds: $885M (3.9%) · 16 clients
Sovereign wealth funds
$885M · 4%
State/municipal govt entities: $800M (3.6%) · 0 clients
State/municipal govt entities
$800M · 4%
Business development companies: $550M (2.4%) · 1 clientsOther investment advisers: $132M (0.6%) · 0 clientsCorporations: $98M (0.4%) · 0 clients
13F AUM over time
$53M
Q2 ’26 · 13F AUM
▼ 92%
42 quarters
Reported Holdings
Q2 2026 · upgrade to Pro for past quarters
↗
★ Position spotlightDNLIDENALI THERAPEUTICS INC · 91.9% of bookThis highlighted stock and its 1Y chart are public
Loading position history…
Security⇅Shares⇅Market Value▼Est. Cost⇅Last Px⇅Est. Return⇅% Portfolio⇅Δ Shares⇅Action⇅
DENALI THERAPEUTICS INC
DNLI· Health Care
1.91MSH$49.1M~$25.72$18.66▼27.4%91.9%▼ 13.6%Reduced
SANA BIOTECHNOLOGY INC
SANA· Health Care
756KSH$2.6M~$3.49$2.37▼32.1%4.9%—Unchanged
8X8 INC NEW
EGHT· Information Technology
991KSH$1.7M~$1.71$2.07▲21.1%3.2%—Unchanged
DNLIDENALI THERAPEUTICS INCReduced
$49.1M· 91.9%· 1.91M SH· ▼ 13.6%· cost $25.72· last $18.66· ▼27.4%
Health Care · COM · DFND
SANASANA BIOTECHNOLOGY INCUnchanged
$2.6M· 4.9%· 756K SH· —· cost $3.49· last $2.37· ▼32.1%
Health Care · COM · DFND
EGHT8X8 INC NEWUnchanged
$1.7M· 3.2%· 991K SH· —· cost $1.71· last $2.07· ▲21.1%
Information Technology · COM · DFND
Sector Breakdown
Q2 2026
Health Care96.8% · $51.8M
Information Technology3.2% · $1.7M
← All 13F filings